Interventional Cardiologists Treat Complex Lesions Within 10 Minutes, With Superb Angiographic Results
NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc. has marked new milestones in stent technology by
demonstrating on a global scale how the firm’s Side-Branch Stent offers
unparalleled ease-of-use and the best option to safely and definitively
treat bifurcation lesions. Tryton transmitted a live satellite feed of a
successful clinical case to an audience of interventional cardiologists
at TCT Asia 2007 in Seoul, Korea, performed by Robert van Geuns, M.D.
Ph.D., Cardiologist, Thoraxcenter, Erasmus Medical Center. Professor
Serruys, Head of the Department of Interventional Cardiology,
Thoraxcenter, Erasmus Medical Center, moderated the event. Tryton’s
Side-Branch Stent was also featured at the American College of
Cardiology’s i2 Summit, where a live satellite feed of a clinical case,
performed by Dr. George Sianos, Senior Interventionalist, Thoraxcenter,
Erasmus Medical Center, was transmitted to demonstrate the ease-of-use
and superb angiographic results that can be predictably achieved by
using Tryton’s stent. The news follows a previous announcement that
revealed the safety of Tryton’s stent during a live case that was
performed in front of 1,000 interventional cardiologists at the Joint
Interventional Meeting (JIM 2007) in Rome.
“Unlike other stents and techniques used to treat bifurcation lesions,
Tryton’s stent is easy to deliver as it uses standard equipment and
techniques compatible with 5 and 6 French guiding catheters,” said Dr.
George Sianos, Senior Interventionalist, Thoraxcenter, Erasmus Medical
Center. “This device has greatly facilitated the treatment of these
patients. The Tryton strategy allows the Interventionist to secure the
side branch and then treat the main vessel with his stent of choice,”
said Dr. Sianos.
“Tryton continues to demonstrate impressive results and growth as it
becomes clear that our stent will eventually provide a new standard of
care, thereby enabling any interventional cardiologists to treat the
entire spectrum of bifurcation lesions they encounter every day,” said
H. Richard Davis, CTO, Tryton Medical, Inc. “The benefits of our
Side-Branch Stent have been witnessed by thousands of interventional
cardiologists in Asia, Europe and America. While others pursue the
elusive goal of treating bifurcation lesions, we are already
definitively treating these lesions. Interventional cardiologists can
quickly grasp how to use our stent to treat complex lesions. Tryton’s
dedicated save-the-side branch approach, allows for securing the
side-branch first, after which the main vessel is stented in a
predictable manner. These benefits simply are not offered with
provisional senting,” Davis added.
Every year, over half a million bifurcation coronary lesions are
sub-optimally treated as no commercially available optimized solution
exists for treating bifurcation lesions. As a result, cardiologists are
forced to use a provisional strategy which avoids the deployment of a
second stent– leaving the side branch vulnerable to thrombosis and
restenosis. “This technology has the capacity to redefine the treatment
of bifurcation lesions and resolve a frequent dilemma of the
interventional cardiologist,” said Professor Patrick W. J. C. Serruys,
M.D., Head of the Department of Interventional Cardiology, Thoraxcenter,
Erasmus Medical Center, Rotterdam, Netherlands.
About Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are
designed to definitively treat bifurcation lesions. 540,000 bifurcation
coronary lesions are sub-optimally treated every year with a variety of
time consuming and technically challenging procedures. No optimized
solution is commercially available for treating bifurcation lesions. As
a result, cardiologists are forced to use a provisional strategy which
avoids the deployment of a second stent– leaving the un-stented side
branch vulnerable to thrombosis and restenosis. The ability to
definitively treat bifurcation lesions will enable PCI-stenting to
become the new standard of care for the treatment of left main coronary
artery disease rather than bypass surgery.
Tryton Medical’s Side-Branch Stent™ has all the characteristics of a
state-of the art workhorse stent, providing proven stent coverage to
bifurcation lesions while eliminating the need for provisional stenting.
For more information on Tryton Medical, Inc., contact Joe Romano,
Partner, HighGround, Inc. at +1 781-279-1320 x 208, jromano@highgroundinc.com
or visit trytonmedical.com.